3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Skin Neoplasms
1
Neoplasms
1
Carcinoma, Merkel Cell
1
Carcinoma, Basal Cell
1
Carcinoma
1
Interventions
pembrolizumab
374
Carboplatin
276
Specimen Handling
265
Nivolumab
252
Magnetic Resonance Spectroscopy
244
Cyclophosphamide
240
Cisplatin
213
Paclitaxel
206
Radiotherapy
195
Biopsy
171
Gemcitabine
155
Dexamethasone
148
durvalumab
143
atezolizumab
126
Rituximab
120
Doxorubicin
115
Bevacizumab
114
Lenalidomide
113
Ipilimumab
111
Radiation
109
Docetaxel
103
Pemetrexed
102
Etoposide
101
fludarabine
97
venetoclax
95
Fluorouracil
92
Capecitabine
92
Radiosurgery
90
Prednisone
89
Oxaliplatin
89
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
MAPRE1 protein, human
×
1 year
×
Clear all
NCT04349436
2026-04-22
ARTACUS
Replimune, Inc.
Phase 1/2
Active not recruiting
69 enrolled